Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

Shahid Beheshti University of Medical Sciences16 enrolled

Overview

In this study 16 Patients diagnosed with Nonarteritic Anterior Ischemic Optic Neuropathy(NSION) who had a sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. In case group Avastin and Triamcinolone will be injected trough vitreal and placebo will be injected in control group. BCVA and Visual field will be then measured in these two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Interventions

Avastin and TriamcinoloneDRUG

1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal

placeboOTHER

2mg placebo

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: * Sudden mono ocular vision loss associated with optic disc edema and positive Marcus Gunn (\<30 days) Exclusion criteria: * Any eye disease except NAION(Nonarteritic Anterior Ischemic Optic Neuropathy) * Neurologic defect * Abnormal ESR, CRP, any history of retina or vitreal surgery * Severe corneal opacity which makes retina examination impossible

Locations (1)

Labbafinejad medical center

Tehran, Iran

RECRUITING

Outcomes

Primary Outcomes

Changes of Best corrected visual acuity(BCVA)

outcome method of measurement: Snellen chart

Time frame: 6 month

Secondary Outcomes

Changes of Visual Field

Automated perimeter

Time frame: 6 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.